PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkeley Heights, NJ 07922 NDC 51991-748-10.

Reported: December 10, 2025 Initiated: November 24, 2025 #D-0216-2026

Product Description

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkeley Heights, NJ 07922 NDC 51991-748-10.

Reason for Recall

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Details

Units Affected
7389 bottles
Distribution
Nationwide within the United States
Location
Berkeley Heights, NJ

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkeley Heights, NJ 07922 NDC 51991-748-10.. Recalled by Breckenridge Pharmaceutical, Inc.. Units affected: 7389 bottles.
Why was this product recalled?
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Which agency issued this recall?
This recall was issued by the FDA Drug on December 10, 2025. Severity: Moderate. Recall number: D-0216-2026.